Current through Register Vol. 43, No. 39, September 26, 2024
Each third-party logistics provider registrant shall meet the
following minimum requirements for operation and the maintenance of
records:
(a) Facilities. Each facility
at which a third-party logistics provider is located shall meet the following
requirements:
(1) Be of suitable size and
construction to facilitate cleaning, maintenance, and proper
operations;
(2) have storage areas
designed to provide adequate lighting, ventilation, temperature, sanitation,
humidity, space, equipment, and security conditions;
(3) have a quarantine area for storage of
prescription-only drugs and devices that are outdated, damaged, deteriorated,
misbranded, adulterated, counterfeit, or suspected of being counterfeit or that
are in immediate or sealed, secondary containers that have been opened or
deemed unfit for distribution;
(4)
be maintained in a clean and orderly condition;
(5) be free from infestation by insects,
rodents, birds, or vermin of any kind;
(6) be in a location separate from any
pharmacy registered by the board or another state;
(7) be a commercial location and not a
personal dwelling or residence; and
(8) have sufficient storage space to maintain
records of all shipments pertaining to third-party logistics for at least five
years.
(b) Security.
(1) Each facility used for third-party
logistics shall be secure from unauthorized entry.
(A) Access from outside the premises shall be
kept to a minimum and be well controlled.
(B) The outside perimeter of the premises
shall be well lighted.
(C) Entry
into areas where prescription-only drugs or devices are held shall be limited
to authorized personnel.
(2) Each facility shall be equipped with an
alarm system to detect entry after hours.
(3) Each facility shall be equipped with a
security system that will provide suitable protection against theft and
diversion. When appropriate, the security system shall provide protection
against theft or diversion that is facilitated or hidden by tampering with
computers or electronic records.
(c) Storage. All prescription-only drugs and
devices shall be stored at appropriate temperatures and under appropriate
conditions in accordance with manufacturer's recommendations to preserve the
stability of these drugs and devices.
(1) If
no storage requirements are established for a prescription-only drug or device,
the drug or device may be held at room temperature, as defined in an official
compendium, to help ensure that its identity, strength, quality, and purity are
not adversely affected.
(2)
Appropriate manual, electromechanical, or electronic temperature and
humidity-recording equipment, devices, logs, or a combination of these means
shall be utilized to document proper storage of prescription-only drugs and
devices at least once during each 24hour period.
(3) The recordkeeping requirements in
subsection (f) shall be followed for all stored prescription-only drugs and
devices.
(d) Examination
of materials.
(1) Upon receipt, each outside
shipping container shall be visually examined to identify and to prevent the
acceptance of prescription-only drugs or devices that are contaminated or
otherwise unfit for distribution. This examination shall be adequate to reveal
container damage that would suggest possible contamination or other damage to
the contents.
(2) Each outgoing
shipment shall be carefully inspected to identify the prescription-only drugs
or devices and to ensure that there is no delivery of prescription-only drugs
or devices that have been damaged in storage or held under improper
conditions.
(3) The recordkeeping
requirements in subsection (f) shall be followed for all incoming and outgoing
prescription-only drugs or devices.
(e) Returned, damaged, and outdated
prescription-only drugs or devices.
(1)
Prescription-only drugs or devices that are outdated, damaged, deteriorated,
misbranded, or adulterated shall be quarantined and physically separated from
other prescription-only drugs and devices until they are destroyed or returned
to their supplier.
(2) Each
prescription-only drug or device whose immediate or sealed outer or sealed
secondary container has been opened or used shall be identified as such and
shall be quarantined and physically separated from other prescription-only
drugs and devices until the drug or device is either destroyed or returned to
the supplier.
(3) If the conditions
under which a prescription-only drug or device has been returned cast doubt on
the drug's or device's safety, identity, strength, quality, or purity, then the
drug or device shall be destroyed or returned to the supplier, unless
examination, testing, or other investigations prove that the drug or device
meets appropriate standards of safety, identity, strength, quality, and purity.
In determining whether or not the conditions under which a drug or device has
been returned cast doubt on the drug's or device's safety, identity, strength,
quality, or purity, the registrant shall consider, among other factors, the
conditions under which the drug or device has been held, stored, or shipped
before or during its return and the condition of the drug or device and its
container, carton, or labeling, as a result of storage or shipping.
(4) The recordkeeping requirements in
subsection (f) shall be followed for all outdated, damaged, deteriorated,
misbranded, or adulterated prescription-only drugs or devices.
(f) Recordkeeping.
(1) Each registrant shall establish and
maintain inventories and records of all transactions regarding the receipt and
distribution or other disposition of prescription-only drugs and devices. These
records shall include the following information:
(A) The source of the drugs and devices,
including the name and principal address of the seller or transferor, and the
address of the location from which the drugs or devices were shipped;
(B) the identity and quantity of the drugs
and devices received and either distributed or disposed of; and
(C) the dates of receipt and either
distribution or other disposition of the drugs and devices.
(2) Inventories and records shall
be made available for inspection and photocopying by an authorized
representative of the board for five years following disposition of the
prescription-only drugs or devices.
(3) The records described in this regulation
that are kept at the inspection site or that can be immediately retrieved by
computer or other electronic means shall be readily available for authorized
inspection during the retention period. Records kept at a central location
apart from the inspection site and not electronically retrievable shall be made
available for inspection within two working days of a request by an authorized
representative of the board.
(4)
Each registrant shall post all current federal and state registrations in a
conspicuous place.
(g)
Written policies and procedures. Each registrant shall establish, maintain, and
adhere to written policies and procedures concerning the receipt, security,
storage, inventory, and distribution of prescription-only drugs and devices,
including policies and procedures for identifying, recording, and reporting
losses or thefts, and for correcting all errors and inaccuracies in
inventories. In addition, each registrant shall establish, maintain, and adhere
to the following written policies and procedures:
(1) A procedure by which the oldest approved
stock of a prescription-only drug or device is distributed first. The procedure
may permit deviation from this requirement, if the deviation is temporary and
appropriate to meet the needs of the receiving facility;
(2) a procedure to be followed for handling
recalls and withdrawals of prescription-only drugs and devices. This procedure
shall be adequate to deal with recalls and withdrawals due to any of the
following:
(A) Any action initiated at the
request of the food and drug administration or other federal, state, or local
law enforcement or other government agency, including the board;
(B) any voluntary action by the manufacturer
to remove defective or potentially defective drugs or devices from the market;
or
(C) any action undertaken to
promote public health and safety by replacing existing merchandise with an
improved product or new package design;
(3) a procedure to ensure that the registrant
prepares for, protects against, and handles any crisis that affects security or
operation of any facility in the event of strike, fire, flood, or other natural
disaster, or other situations of local, state, or national emergency;
and
(4) a procedure to ensure that
all outdated prescription-only drugs or devices are segregated from other drugs
and devices and either returned to the manufacturer or destroyed. This
procedure shall provide for written documentation of the disposition of
outdated prescription-only drugs or devices. Each registrant shall maintain
this documentation for ive years after disposition of each outdated
prescription-only drug or device.
(h) Responsible persons. Each registrant
shall establish and maintain a list of officers, directors, managers, and other
persons in charge of prescription-only drug and device distribution, storage,
and handling, including a description of their duties and a summary of their
qual-iications. This list shall be made available for inspection by the
board.
(i) Compliance with federal,
state, and local law.
(1) Each registrant that
deals in controlled substances shall register with the DEA.
(2) Each registrant shall permit the board's
authorized personnel to enter and inspect the registrant's premises and
delivery vehicles and to audit the records and written operating procedures, at
reasonable times and in a reasonable manner, to the extent authorized by
law.
(3) Each registrant shall
operate in accordance with the requirements of
21
U.S.C. 360ee e, or any implementing
regulation.